Literature DB >> 20138825

SOX2 modulates alternative splicing in transitional cell carcinoma.

Chun-Liang Tung1, Pei-Hsuan Hou, Yung-Ling Kao, Yu-Wen Huang, Chiung-Chun Shen, Yi-Hsin Cheng, Shu-Fen Wu, Moon-Sing Lee, Chin Li.   

Abstract

Aberrant alternative splicing of key cellular regulators may play a pivotal role in cancer development. To investigate the potential influence of altered alternative splicing on the development of transitional cell carcinoma (TCC), splicing activity in the TCC cell lines TSGH8301 and BFTC905 was examined using the SV40-immortalized uroepithelial cell line SV-HUC-1 as a reference. Our results indicate a significant alteration in splice site selection in the TCC cell lines. By gene expression profiling and subsequent validation, we discovered that sex-determining region Y-box protein 2 (SOX2) is specifically upregulated in BFTC905. Furthermore, ectopic expression of SOX2 modulates alternative splicing of the splicing reporter in vivo. More significantly, using an in vitro pull-down assay, it was found that SOX2 exhibits RNA-binding capability. Our observations suggest that SOX2 modulates alternative splicing by functioning as a splicing factor. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20138825     DOI: 10.1016/j.bbrc.2010.02.010

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  DNA methylation levels and long-term trihalomethane exposure in drinking water: an epigenome-wide association study.

Authors:  Lucas A Salas; Mariona Bustamante; Juan R Gonzalez; Esther Gracia-Lavedan; Victor Moreno; Manolis Kogevinas; Cristina M Villanueva
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

Review 2.  Sox2: regulation of expression and contribution to brain tumors.

Authors:  Sheila Mansouri; Romina Nejad; Merve Karabork; Can Ekinci; Ihsan Solaroglu; Kenneth D Aldape; Gelareh Zadeh
Journal:  CNS Oncol       Date:  2016-05-27

3.  Promotion of direct reprogramming by transformation-deficient Myc.

Authors:  Masato Nakagawa; Nanako Takizawa; Megumi Narita; Tomoko Ichisaka; Shinya Yamanaka
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

Review 4.  Role of SOX family of transcription factors in central nervous system tumors.

Authors:  Arlet M Acanda de la Rocha; Nicolas Sampron; Marta M Alonso; Ander Matheu
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

5.  Predictive value of Sox2 expression in transurethral resection specimens in patients with T1 bladder cancer.

Authors:  Jun Ruan; Bingbing Wei; Zhuoqun Xu; Shudong Yang; You Zhou; Minhong Yu; Jiabei Liang; Ke Jin; Xing Huang; Peng Lu; Huan Cheng
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

6.  Overexpression of SOX2 promotes migration, invasion, and epithelial-mesenchymal transition through the Wnt/β-catenin pathway in laryngeal cancer Hep-2 cells.

Authors:  Ning Yang; Lian Hui; Yan Wang; Huijun Yang; Xuejun Jiang
Journal:  Tumour Biol       Date:  2014-05-16

7.  Interaction of Sox2 with RNA binding proteins in mouse embryonic stem cells.

Authors:  Paulo P Amaral; Pär G Engström; Samuel C Robson; Michael L Nielsen; Tony Kouzarides; Gonçalo Castelo-Branco
Journal:  Exp Cell Res       Date:  2019-05-09       Impact factor: 3.905

Review 8.  SOX2 and cancer: current research and its implications in the clinic.

Authors:  Kasia Weina; Jochen Utikal
Journal:  Clin Transl Med       Date:  2014-07-04

9.  SOX2 suppresses the mobility of urothelial carcinoma by promoting the expression of S100A14.

Authors:  Moon-Sing Lee; Wan-Ting Hsu; Yi-Fang Deng; Ching-Wei Lin; Erh-Ying Weng; Hsin-Ping Chang; Shu-Fen Wu; Chin Li
Journal:  Biochem Biophys Rep       Date:  2016-06-25

10.  Utility of SOX2 and Livin Co-Expression in the Prognosis of Bladder Cancer With Bilharzial and Non-Bilharzial Bladder Status.

Authors:  Mariana Fathy Gayyed; Ehab Rifat Tawfiek
Journal:  World J Oncol       Date:  2015-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.